Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Writes for:

Latest From Andrew McConaghie

GSK Aims To Launch 13 Blockbusters In Five Years

GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.

Commercial Companies

J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints

If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.

Commercial Clinical Trials

Novavax Could Be The Next Biotech Winner In COVID-19 Vaccines

After years of setbacks, Novavax is on the cusp of success with its COVID-19 vaccine - but a rapid scale up of manufacturing and commercial operations will be a huge challenge.

Commercial Companies

Coronavirus Update: Pfizer CEO Thinks Vaccine Price Rise Likely Post-Pandemic

Companies will raise their COVID-19 vaccine prices once the pandemic is over – but key long-term data will determine which comes out on top.

Companies Commercial

Boehringer Explores ‘Dark Antigens’ With Enara In Potential $1bn Deal

Announcing its first big pharma deal, the Oxford-based biotech says there could be more to come – with mRNA pioneers also interested in shining a light on hidden drug targets.

Companies Commercial

Don’t Write Actemra Off Yet: Roche Drug Found To Be Lifesaving In COVID-19

After failing in five earlier trials, Actemra shows significant life-saving benefits for patients with severe COVID-19.

Companies Commercial
See All
UsernamePublicRestriction

Register